The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European ...

07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of ...

Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States Chemistry-Biology Interface Graduate Training Program, Johns ...

With the publication of this study, guselkumab is now the third IL-23 inhibitor to meet its primary efficacy endpoint in this population, joining the already approved mirikizumab and risankizumab. 3,4 ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

The Rock had an inspirational message to close out the year. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. It's common for The Rock to ...

Glycogen storage disease (GSD) refers to a group of rare genetic conditions that affect how the body stores and breaks down glycogen. The most common type is type I, also called von Gierke disease ...